Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on March 17, 2017. The filing addresses a notice received from the New York Stock Exchange (NYSE) regarding the Company's failure to comply with continued listing requirements due to the untimely filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and audit status rather than financial performance data.
Material Changes and Events
- Listing Non-Compliance: The Company received notice from the NYSE that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to the failure to timely file its 2016 Form 10-K.
- Audit Delays: The delay is attributed to the inability of the Company and its independent auditor, Ernst & Young LLP (E&Y), to complete reviews of historical revenue recognition practices associated with the Tysabri royalty stream by the extended filing deadline.
- Ongoing Audit Scope: E&Y and the Company are focused on completing audit procedures, including reviews of deferred tax assets and related effects at Omega Pharma Invest N.V.
Outlook, Risks, and Management Commentary
The NYSE has granted the Company six months from March 16, 2017, to file the Form 10-K and regain compliance. If the filing is not made within this period, the NYSE may grant a further extension of up to six months at its discretion. However, the exchange reserves the right to commence delisting proceedings at any time if circumstances warrant.
Management highlighted significant risks in the forward-looking statements, including:
- Potential inability to remediate material weaknesses in internal control over financial reporting.
- Risk of restating financial statements, which could lead to additional tax liabilities for 2016 and prior years.
- Potential breach of Irish company legislation regarding prior financial statements, resulting in expenses and penalties.
- Uncertainty regarding the time, effort, and expense required to complete the 2016 Form 10-K.
Key Facts for Investor Verification
- Verify the current status of the Form 10-K for the fiscal year ended December 31, 2016, and whether it has been filed.
- Monitor the NYSE's stance on the Company's listing status and any potential delisting proceedings.
- Assess the progress of the audit regarding Tysabri royalty revenue recognition and deferred tax assets at Omega Pharma Invest N.V.
- Review subsequent filings for any announcements regarding financial statement restatements or material weaknesses in internal controls.